Head-To-Head Comparison: Alpha Cognition (NASDAQ:ACOG) versus Cognition Therapeutics (NASDAQ:CGTX)

Cognition Therapeutics (NASDAQ:CGTX) and Alpha Cognition (NASDAQ:ACOG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Profitability

This table compares Cognition Therapeutics and Alpha Cognition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-150.93%	-100.82%
Alpha Cognition	N/A	N/A	-344.17%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cognition Therapeutics and Alpha Cognition, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	0	1	5	1	3.00
Alpha Cognition	0	0	1	0	3.00

Cognition Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 1,598.37%. Alpha Cognition has a consensus target price of $20.00, suggesting a potential upside of 262.32%. Given Cognition Therapeutics’ higher possible upside, research analysts clearly believe Cognition Therapeutics is more favorable than Alpha Cognition.

Risk & Volatility

Cognition Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.5, meaning that its stock price is 150% more volatile than the S&P 500.

Institutional and Insider Ownership

43.3% of Cognition Therapeutics shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by insiders. Comparatively, 31.5% of Alpha Cognition shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cognition Therapeutics and Alpha Cognition”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$25.79 million	($0.87)	-0.51
Alpha Cognition	N/A	N/A	-$13.77 million	($2.56)	-2.16

Alpha Cognition is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Cognition Therapeutics beats Alpha Cognition on 7 of the 11 factors compared between the two stocks.

About Cognition Therapeutics

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

About Alpha Cognition

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.